TAVI in low-risk patients

  • TAVI with SAPIEN 3 compared to surgery, in the PARTNER 3 Trial, has demonstrated superior clinical outcomes and improved quality of life for severe aortic stenosis (sAS) patients with low surgical risk1,2
  • Based on the evidence, the 2021 ESC/EACTS VHD Guidelines recommend TF-TAVI as the preferred mode of intervention in all sAS patients* ≥75 years of age which includes those at low surgical risk3
  • Additional patient groups <75 years of age are suitable for TF-TAVI based on an evaluation of clinical, anatomical, and procedural factors3

*With a treatment indication

TAVI can provide optimal outcomes to your low-risk patients1

In the PARTNER 3 Trial, TAVI, compared with surgery, resulted in superior clinical outcomes, improved quality of life and faster discharge for sAS patients.1*

Results

46%
reduced risk at 1 year in all-cause death, stroke or rehospitalisation
(8.5 % vs a 15.1 % for surgery), p = 0.0011

1%
death or disabling stroke at 1 year
(vs 2.9 % for surgery), p = 0.031

4-day
shorter length of hospital stay
(3 vs 7 days for surgery), p>0.0011

1-, 6- and 12- month
improvement in health status (compared to surgery)2

* The PARTNER 3 Trial proved SAPIEN 3 TAVI is superior to surgery on the primary endpoint (all-cause death, all stroke or rehospitalisation) and multiple prespecified secondary endpoints in low-risk patients.

Explore the full PARTNER 3 Trial

2021 ESC/EACTS VHD Guideline recommendations for aortic stenosis management3

Real-world studies, registries and clinical trials such as the PARTNER 3 Trial have informed the 2021 update to the ESC/EACTS VHD Guidelines:

  • TF-TAVI is now recommended in all sAS patients* ≥75 years of age including those at low surgical risk3
  • Additional patient groups <75 years of age are suitable for TF-TAVI based on an evaluation of clinical, anatomical, and procedural factors3

Your patients with sAS* aged ≥75 years can benefit from the urgent treatment they need with a TF-TAVI

*With a treatment indication

Explore the new guidelines

Referencias:

1 Mack MJ, Leon MB, Thourani VH, et al. N Engl J Med. 2019;380(18):1695-1705.
2 Baron SJ, Magnuson EA, Lu M, et al. J Am Coll Cardiol 2019;74(23):2833-2842.
3 Vahanian A, et al. Eur Heart J. 2021; ehab395.

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

PP--EU-0761 v3.0